The New Frontier in Cancer Therapy—And the Political Arena Behind It
In the packed halls of ASCO 2025, amid a sea of abstract posters and hushed clinical optimism, one phrase echoed ...
When the Data Lags Behind the Pain: Racial Disparities in Early-Onset Colorectal Cancer Take Center Stage
The silence wasn’t in the data—it was in the delay. That was the message that reverberated across the oncology world ...
Crossing Borders: The Quiet Exodus of American Physicians to Canada
In recent months, a notable and unexpected phenomenon has quietly unfolded, reshaping conversations among medical professionals across North America. Prompted ...
From Crisis to Controversy: How States Are Allocating Their $50 Billion Opioid Settlement
When billions of dollars flow into state budgets, decisions about allocation quickly transcend fiscal planning—they become moral judgments. This reality ...
Beyond Labels: The Policy Battle Brewing Over Ultra-Processed Foods
On a crisp May morning at the Axios Future of Health Summit, an audience of nutritionists, policymakers, and influencers erupted ...
Physical Indicators of Dehydration in Medical Patients
Medical patients displaying the physical indicators of dehydration may also be experiencing medical abuse. Read this article to learn the ...
Debunking Certainty: How the MAHA Report by Robert F. Kennedy Jr. Thrives on Logical Fallacies
When Robert F. Kennedy Jr. released the eagerly anticipated yet deeply contentious MAHA report earlier this year, it instantly polarized ...
Decoding Hope: The Johns Hopkins AI Algorithm Transforming Pancreatic Cancer Treatment Decisions
It began quietly, almost unnoticed—until the digital landscape ignited. Researchers at Johns Hopkins University unveiled an artificial intelligence-driven blood test ...
Trending Treatments: The Intersection of Social Media Virality and Clinical Significance at ASCO 2025
The digital buzz surrounding the American Society of Clinical Oncology (ASCO) Annual Meeting reached fever pitch this May, transforming the ...
Compound Controversy: The FDA’s Political Tug-of-War Over Ozempic and Wegovy Alternatives
In early May 2025, countless Americans awoke to unsettling news—this time not about a virus, but about access to vital ...
Mpox Reemerges in Africa: The Viral Threat Amid Vaccine Shortages and Political Abandonment
In a bustling hospital in Addis Ababa, Ethiopia, patients queue anxiously, nurses rush between packed wards, and health officials tally ...
Unseen Threats and Familiar Doubts: India’s Fresh Battle with the Omicron NB.1.8.1 Variant
As the sun rose over New Delhi in early May, the bustling city awoke to troubling headlines. COVID-19 was surging ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more